Drug General Information
Drug ID	D05FIJ
Former ID	DIB010359
Drug Name	GSK2816126
Indication	Cancer [ICD9: 140-229; ICD10:C00-C96]		Phase 1	[524671]
Company	Glaxosmithkline
Structure		Download 2D MOL 3D MOL
Target and Pathway
Target(s)	Enhancer of zeste homolog 2	Target Info	Modulator	[550506]
KEGG Pathway	MicroRNAs in cancer
NetPath Pathway	IL2 Signaling Pathway
Reactome	PRC2 methylates histones and DNA
	Oxidative Stress Induced Senescence
	PKMTs methylate histone lysines
WikiPathways	Interactome of polycomb repressive complex 2 (PRC2)
	Endoderm Differentiation
	Integrated Pancreatic Cancer Pathway
	Histone Modifications
	Cell Differentiation - meta
	miRs in Muscle Cell Differentiation
	miR-targeted genes in muscle cell - TarBase
	miR-targeted genes in lymphocytes - TarBase
	miR-targeted genes in epithelium - TarBase
References
Ref 524671	ClinicalTrials.gov (NCT02082977) A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK2816126 in Subjects With Relapsed/Refractory Diffuse Large B Cell and Transformed Follicular Lymphoma. U.S. National Institutes of Health.
Ref 550506	National Cancer Institute Drug Dictionary (drug id 756211).

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.